Schlumberger Ltd Exec: targeting 2014 EPS growth in double digits, and see solid growth in North America though pricing will be under pressure - conf call comments
- EPS and margins could be lower in Q1 due to normal seasonality.
US surgeon general Lushniak to release report today that expands the list of diseases that cigarette smoking has been shown to cause (UPDATE)
- Report cites scientific data that conclusively demonstrates smoking raises the risk of additional diseases not previously listed as smoking risks: type 2 diabetes, erectile dysfunction, rheumatoid arthritis, macular degeneration, and two more kinds of cancer (liver and colorectal cancers).
-
Recent downdraft in European equities price action said to related to potential sovereign downgrade chatter in region
- Some dealers trying to push chatter of a potential German sovereign downgrade.
- Other dealer note the option expiration for today. the Dax option expired at 09:00 ET (14:00 GMT)
- Other dealer note the option expiration for today. the Dax option expired at 09:00 ET (14:00 GMT)
Switzerland and EU start negotiations on taxation of savings income
Bern, 17.01.2014 - Switzerland and the EU have officially started negotiations on revising the taxation of savings agreement. Today in Bern, State Secretary Jacques de Watteville met his counterpart Heinz Zourek, Director General of the European Commission's Taxation and Customs Union Directorate-General. The aim of the meeting was to take stock of the situation and establish the technical details for the negotiations.
The meeting followed on from the Federal Council's adoption on 18 December 2013 of the negotiation mandate to revise the taxation of savings agreement with the European Union (EU). On 14 May 2013, the European Commission, for its part, was instructed by the Economic and Financial Affairs Council (ECOFIN) to negotiate an amendment of this agreement with Switzerland.
In this way, the EU wants to make sure that the agreement is amended in line with the planned revision of its own Savings Taxation Directive. The aim of the revision is to close the gaps and prevent people from evading the taxation of their interest income by interposing bogus companies or resorting to certain financial instruments. International developments in this area should also be taken into account in the negotiations. The negotiating parties have agreed to hold regular meetings in the first half of 2014.
The State Secretary and his EU counterpart also discussed business taxation. A solution will be sought which is in line with international standards, strengthens Switzerland as a business location and is financially viable for the Confederation and the cantons.Gapping up
In reaction to strong earnings/guidance: SWKS +13.6%, STI +2.9%, FHN +1.3%, SLB +1%, MS +0.9%.
M&A news: MIL +6.1% (to acquire a 100% interest in the FESIL AS Group for ~ 500 mln Norwegian Krone (~ $82 mln); 'not expected to have a material effect on our financial ratios or cause any dilution to our shareholders' equity'), S +3% and TMUS +2.5% (ongoing M&A speculation- Sprint has financing proposals from banks for T-Mobile bid, according to reports).
A few financial related names slightly higher: HSBC +1.3%, C +1%, PUK +1%.
Metals/mining stocks trading higher: MT +4%, IAG +2.8%, RIO +2%, BBL +1.5%, BHP +0.9%.
A few solar names are modestly higher: SPWR +3.3%, RSOL +1.6%, JKS +1.5%, FSLR +0.4%
Other news: ARQL +28.4% (provides updates on clinical trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib; Data Monitoring Committee approves continuation of Phase 3 METIV-HCC liver cancer trial following safety and pharmacokinetic analyses), NIHD +28.3% ( announces agreement with Apple (AAPL) to bring iPhone to its Nextel Brazil operations ), NLST+8.5% (announces the USPTO has issued Notices of Allowance for two of co's pending patent applications covering core aspects of hybrid memory systems that combine DRAM and FLASH memory technologies), CTIC +7.8% (seeing continued momentum - up 60%+ month to date), KERX +7.1% (announces marketing approval of ferric citrate in Japan), ARIA +6.5% (announces the commercial availability of Iclusig for patients with refractory Philadelphia-positive leukemias in the U.S.), CTRP +3.3% (positive comments by Raymond James analyst on CNBC), TWTR +3.2% (seeing reports that co is nearing a deal with payments startup Stripe; initiated with Buy and $75 at Stifel), TSCO +3.1% (TSCO to replace LIFE in the S&P 500), TS +2.8% (still checking), EA +2.1% (on NPD data - WSJD details news that video game sales fell 17% in December in the US), STRM +1.8% (signs definitive agreement to acquire Unibased Systems Architecture; terms not disclosed), RRTS +1.6% (RRTS to replace ALGN in the S&P SmallCap 600), HLF +1.4% (modestly rebounding from NUS related concerns), SAND +1% ( announces 13.4 g/t over 9.5 meters at Bachelor Lake),GSK +1% (still checking), ILMN +0.6% (outlines strategic roadmap for market expansion), QIHU +0.6% (China search traffic market share increasing to ~ 35% in 2014, according to Marbridge ), ALGN +0.5% ( ALGN to replace RRTS in the S&P MidCap 400)
Analyst comments: OTIV +3.9% (initiated with a Outperform at Northland Capital; tgt $5.25 ), MMP +1.5% (initiated with a Buy at Wunderlich), AGN +1% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), TOT +0.7% (upgraded to Buy from Neutral at Citigroup), STO +0.6% (upgraded to Buy from Hold at Deutsche)
M&A news: MIL +6.1% (to acquire a 100% interest in the FESIL AS Group for ~ 500 mln Norwegian Krone (~ $82 mln); 'not expected to have a material effect on our financial ratios or cause any dilution to our shareholders' equity'), S +3% and TMUS +2.5% (ongoing M&A speculation- Sprint has financing proposals from banks for T-Mobile bid, according to reports).
A few financial related names slightly higher: HSBC +1.3%, C +1%, PUK +1%.
Metals/mining stocks trading higher: MT +4%, IAG +2.8%, RIO +2%, BBL +1.5%, BHP +0.9%.
A few solar names are modestly higher: SPWR +3.3%, RSOL +1.6%, JKS +1.5%, FSLR +0.4%
Other news: ARQL +28.4% (provides updates on clinical trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib; Data Monitoring Committee approves continuation of Phase 3 METIV-HCC liver cancer trial following safety and pharmacokinetic analyses), NIHD +28.3% ( announces agreement with Apple (AAPL) to bring iPhone to its Nextel Brazil operations ), NLST+8.5% (announces the USPTO has issued Notices of Allowance for two of co's pending patent applications covering core aspects of hybrid memory systems that combine DRAM and FLASH memory technologies), CTIC +7.8% (seeing continued momentum - up 60%+ month to date), KERX +7.1% (announces marketing approval of ferric citrate in Japan), ARIA +6.5% (announces the commercial availability of Iclusig for patients with refractory Philadelphia-positive leukemias in the U.S.), CTRP +3.3% (positive comments by Raymond James analyst on CNBC), TWTR +3.2% (seeing reports that co is nearing a deal with payments startup Stripe; initiated with Buy and $75 at Stifel), TSCO +3.1% (TSCO to replace LIFE in the S&P 500), TS +2.8% (still checking), EA +2.1% (on NPD data - WSJD details news that video game sales fell 17% in December in the US), STRM +1.8% (signs definitive agreement to acquire Unibased Systems Architecture; terms not disclosed), RRTS +1.6% (RRTS to replace ALGN in the S&P SmallCap 600), HLF +1.4% (modestly rebounding from NUS related concerns), SAND +1% ( announces 13.4 g/t over 9.5 meters at Bachelor Lake),GSK +1% (still checking), ILMN +0.6% (outlines strategic roadmap for market expansion), QIHU +0.6% (China search traffic market share increasing to ~ 35% in 2014, according to Marbridge ), ALGN +0.5% ( ALGN to replace RRTS in the S&P MidCap 400)
Analyst comments: OTIV +3.9% (initiated with a Outperform at Northland Capital; tgt $5.25 ), MMP +1.5% (initiated with a Buy at Wunderlich), AGN +1% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), TOT +0.7% (upgraded to Buy from Neutral at Citigroup), STO +0.6% (upgraded to Buy from Hold at Deutsche)
+------------------------------------------------------------------------------+
BN 01/17 12:53 *DONGFENG SAID TO AGREE IN PRINCIPLE TO PEUGEOT DEAL STRUCTURE
+------------------------------------------------------------------------------+
Dongfeng Said to Agree in Principle to Peugeot Deal Structure 2014-01-17 12:56:06.397 GMT
By Brian Lysaght Jan. 17 (Bloomberg) -- Story: {NSN MZJQHJ6K510N <go>}
Link to Company News:{489 HK <Equity> CN <GO>} Link to Company News:{UG FP <Equity> CN <GO>}
For Related News and Information: First Word scrolling panel: {FIRST<GO>} First Word newswire: {NH BFW<GO>}
To contact the editor responsible for this story: Brian Lysaght at +44-20-7330-7908 or blysaght@bloomberg.net
--> +6.5% Pre Market
Ariad Pharmaceuticals Inc Iclusig is commercially available for patients with Refractory Philadelphia-Positive Leukemias in the U.S.
- Announced the commercial availability of Iclusig(ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.
- Last month, the U.S. Food and Drug Administration (FDA) approved revised U.S. Prescribing Information (USPI) and a communications Risk Evaluation and Mitigation Strategy (REMS) for Iclusig that allowed for the immediate resumption of its marketing and commercial distribution. The USPI includes a revised indication statement and boxed warning, updated safety information and recommendations regarding dosing considerations for prescribers. Iclusig is now indicated for the treatment of adult patients with:
- T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, or
- Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia for whom no other tyrosine-kinase inhibitor therapy is indicated.
The starting dose of Iclusig remains 45 mg daily.
- On November 1, 2013, there were approximately 640 patients receiving Iclusig obtained through commercial channels in the U.S. Since then, Iclusig was made available through emergency and single-patient investigational new drug (IND) applications, which were reviewed and approved by the FDA on a case-by-case basis. The FDA has approved more than 370 INDs since early November, and more than 300 patients have received Iclusig at no cost through this process. ARIAD expects most of these patients, many of whom received a three-month supply of Iclusig, to transition from the IND program to commercial therapy by the end of the first quarter of 2014. The Iclusig IND program is now closed to new patients with Philadelphia-positive leukemias.
- In addition to providing specialty pharmacy services, Biologics will help transition patients from the Iclusig IND program to commercial product. Biologics will further support the ARIAD Patient Access and Support Services (ARIAD PASS) program by managing ARIADs reimbursement and patient access services and co-pay support programs by conducting benefits investigations and prior authorizations to assess and assist with patient eligibility. Iclusig is currently priced in the U.S. at approximately $125,000 per year. The new annual cost of Iclusig is approximately a 17 percent premium to second-generation TKIs.
- Last month, the U.S. Food and Drug Administration (FDA) approved revised U.S. Prescribing Information (USPI) and a communications Risk Evaluation and Mitigation Strategy (REMS) for Iclusig that allowed for the immediate resumption of its marketing and commercial distribution. The USPI includes a revised indication statement and boxed warning, updated safety information and recommendations regarding dosing considerations for prescribers. Iclusig is now indicated for the treatment of adult patients with:
- T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, or
- Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia for whom no other tyrosine-kinase inhibitor therapy is indicated.
The starting dose of Iclusig remains 45 mg daily.
- On November 1, 2013, there were approximately 640 patients receiving Iclusig obtained through commercial channels in the U.S. Since then, Iclusig was made available through emergency and single-patient investigational new drug (IND) applications, which were reviewed and approved by the FDA on a case-by-case basis. The FDA has approved more than 370 INDs since early November, and more than 300 patients have received Iclusig at no cost through this process. ARIAD expects most of these patients, many of whom received a three-month supply of Iclusig, to transition from the IND program to commercial therapy by the end of the first quarter of 2014. The Iclusig IND program is now closed to new patients with Philadelphia-positive leukemias.
- In addition to providing specialty pharmacy services, Biologics will help transition patients from the Iclusig IND program to commercial product. Biologics will further support the ARIAD Patient Access and Support Services (ARIAD PASS) program by managing ARIADs reimbursement and patient access services and co-pay support programs by conducting benefits investigations and prior authorizations to assess and assist with patient eligibility. Iclusig is currently priced in the U.S. at approximately $125,000 per year. The new annual cost of Iclusig is approximately a 17 percent premium to second-generation TKIs.
Turkey Central Bank (TCMB) Survey of Expectations
- Cuts 2014 GDP forecast from 3.7% to 3.2%
- Maintains End-2014 Inflation:at 7.4%
{http://www.tcmb.gov.tr/yeni/eng/}
- Maintains End-2014 Inflation:at 7.4%
{http://www.tcmb.gov.tr/yeni/eng/}
Stocks to keep on radar following Mad Money comments
Stocks with favorable mention: LOCK, SSYS, ISIL, EXEL, LOW, DIS
Stocks with unfavorable mention: VJET, LSI, SGMO
Stocks with unfavorable mention: VJET, LSI, SGMO
- Others to note: GALE - down 6% following CEO appearance on MadMoney and mention that investors should take profits